Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial

Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial

Abstract Cardiovascular adverse events (CVAE) are clinically relevant side effects during treatment with the proteasome inhibitor carfilzomib. We investigated the predictive value of cardiac biomarkers for onset of CVAE in patients with newly diagnosed high-risk multiple myeloma treated with isatuxi...

Full description

Saved in:
Bibliographic Details
Main Authors: Lisa B. Leypoldt, Linlin Guo, Britta Besemer, Mathias Hänel, Marc-S. Raab, Christoph Mann, Christian S. Michel, Hans Christian Reinhardt, Igor Wolfgang Blau, Martin Görner, Yon-Dschun Ko, Maike de Wit, Hans Salwender, Christof Scheid, Ullrich Graeven, Rudolf Peceny, Peter Staib, Annette Dieing, Hartmut Goldschmidt, Carsten Bokemeyer, Tanja Zeller, Dirk Westermann, Katja C. Weisel, Raphael Twerenbold, Antonia Beitzen-Heineke
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Cardio-Oncology
Online Access:https://doi.org/10.1186/s40959-025-00358-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40959-025-00358-x

Similar Items